Narsico, Joana Marie B.
HRN: 24-58-02 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/16/2024
CO-AMOXICLAV 625MG (TAB)
02/16/2024
02/23/2024
PO
625mg
BID
Thinly MSAF; RMLE And Repair
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes